Septerna, Inc. (NASDAQ:SEPN) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Septerna, Inc. (NASDAQ:SEPN) have earned an average rating of “Moderate Buy” from the eleven research firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $52.4444.

SEPN has been the topic of several analyst reports. Guggenheim lifted their price objective on Septerna from $45.00 to $51.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. JPMorgan Chase & Co. increased their target price on Septerna from $38.00 to $48.00 and gave the company an “overweight” rating in a report on Wednesday, August 19th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Septerna in a research note on Friday, July 17th. Truist Financial boosted their price objective on Septerna from $35.00 to $43.00 and gave the company a “buy” rating in a research report on Wednesday, July 1st. Finally, JonesTrading raised their target price on shares of Septerna from $43.00 to $62.00 and gave the stock a “buy” rating in a report on Thursday, August 13th.

Septerna Price Performance

NASDAQ:SEPN opened at $38.69 on Wednesday. Septerna has a 1 year low of $15.41 and a 1 year high of $51.10. The stock’s fifty day moving average price is $38.10 and its two-hundred day moving average price is $31.87. The company has a market cap of $1.81 billion, a P/E ratio of -71.65 and a beta of 2.30.

Septerna (NASDAQ:SEPN) last posted its earnings results on Monday, August 10th. The company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.14. Septerna had a negative net margin of 24.51% and a negative return on equity of 9.57%. The business had revenue of $26.75 million for the quarter, compared to analyst estimates of $19.22 million. On average, analysts expect that Septerna will post -1.41 earnings per share for the current fiscal year.

Insider Activity

In other news, COO Elizabeth Bhatt sold 25,000 shares of the business’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $44.00, for a total transaction of $1,100,000.00. Following the sale, the chief operating officer owned 174,209 shares in the company, valued at approximately $7,665,196. The trade was a 12.55% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Samira Shaikhly sold 2,178 shares of the company’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $35.18, for a total transaction of $76,622.04. Following the completion of the sale, the insider directly owned 793 shares in the company, valued at $27,897.74. This represents a 73.31% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 37,178 shares of company stock valued at $1,532,154. Corporate insiders own 5.80% of the company’s stock.

Hedge Funds Weigh In On Septerna

Large investors have recently made changes to their positions in the business. TRV GP V LLC bought a new position in Septerna during the 2nd quarter valued at approximately $208,160,143. TRV GP VI LLC bought a new stake in Septerna in the second quarter worth $141,048,460. BlackRock Inc. purchased a new stake in shares of Septerna in the second quarter worth $64,706,000. Jupiter Topco LLC purchased a new stake in shares of Septerna in the second quarter worth $43,723,000. Finally, Primecap Management Co. CA bought a new position in shares of Septerna during the second quarter valued at $39,096,000.

Septerna Company Profile

Septerna, Inc is a clinical-stage biotechnology company focused on discovering and developing oral small-molecule medicines that target G protein-coupled receptors (GPCRs). GPCRs are a large class of cell-surface proteins involved in numerous biological processes and are established targets for therapies across a range of diseases.

The company uses its proprietary Native Orthosteric Ligand Discovery platform to study GPCRs in their native cellular environments and identify small-molecule compounds that can modulate these receptors.